Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Rac1 palmitoylation is required for cardiac stress adaptation and regulation of protein kinase A signaling
James P. Teuber, Rachel E. Scissors, Arasakumar Subramani, Nageswara Madamanchi, Matthew J. Brody
James P. Teuber, Rachel E. Scissors, Arasakumar Subramani, Nageswara Madamanchi, Matthew J. Brody
View: Text | PDF
Research Article Cardiology Cell biology

Rac1 palmitoylation is required for cardiac stress adaptation and regulation of protein kinase A signaling

  • Text
  • PDF
Abstract

Cardiac hypertrophy is a common adaptation to cardiovascular stress and often a prelude to heart failure. We examined how S-palmitoylation of the small GTPase, Ras-related C3 botulinum toxin substrate 1 (Rac1), impacts cardiomyocyte stress signaling. Mutation of the Cys-178 palmitoylation site impaired activation of Rac1 when overexpressed in cardiomyocytes. Cardiomyocyte-specific Rac1 conditional knockin (Rac1cKI) mice expressing a Rac1C178S mutant protein exhibited normal cardiac structure and function but developed more severe cardiac hypertrophy in response to angiotensin II (AngII) infusion, cardiomyocyte-specific overexpression of AngII type 1 receptor (AT1R), and cardiac pressure overload. Moreover, pressure overload and AT1R overexpression evoked cardiac failure phenotypes in Rac1cKI mice not observed in controls. Mechanistically, Rac1cKI hearts and cardiomyocytes genetically resistant to Rac1 S-palmitoylation had a profound increase in protein kinase A (PKA) substrate phosphorylation in response to acute β-adrenergic stimulation, as did Rac1cKI hearts subjected to chronic AngII treatment, AT1R overexpression, or pressure overload that correlates with more advanced heart failure phenotypes. This was not associated with increased PKA enzymatic activity, suggesting potential deficits in phosphatase activity at PKA-regulated phospho-sites. Taken together, this study suggests Rac1 S-palmitoylation dampens adrenergic drive and PKA-dependent modulation of the phospho-proteome in response to cardiovascular stress, revealing essential functions for S-acylated Rac1 in cardiac adaptation.

Authors

James P. Teuber, Rachel E. Scissors, Arasakumar Subramani, Nageswara Madamanchi, Matthew J. Brody

×

Figure 3

Cardiomyocyte-specific Rac1 conditional knockin mice develop more severe cardiac hypertrophy in response to AngII.

Options: View larger image (or click on image) Download as PowerPoint
Cardiomyocyte-specific Rac1 conditional knockin mice develop more severe...
(A) Representative images of whole hearts and H&E- and Picrosirius red–stained (PSR-stained) cardiac sections from control and Rac1 cardiomyocyte-specific knockin mice infused with saline or AngII (3 mg/kg/d) for 14 days. Scale bars: 5 mm (whole hearts), 1 mm (H&E), 100 μm (PSR). (B) Heart weight–to–body weight (HW/BW) and (C) heart weight–to–tibia length (HW/TL) ratios of Myh6-Cre alone, Rac1cKI/cKI, and Rac1cKI/cKI; Myh6-Cre mice treated with saline or AngII for 14 days. Echocardiographic assessment of (D) fractional shortening (FS) and (E) left ventricular inner diameter at diastole (LVIDd) following 2 weeks of saline or AngII infusion. Quantification of (F) Nppa and (G) Postn transcript levels by qPCR in mouse hearts of the indicated genotype and treatment. (H) Quantification of fibrotic area from PSR-stained sections of saline or AngII-treated control and Rac1cKI mice. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 2-way ANOVA with post hoc Tukey’s multiple-comparison test. NS, not significant. n = 7–15 per group for B and C, n = 4–15 per group for D and E, n = 4–8 per group for F and G, n = 4–11 per group for H.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts